The Mycophenolate Pregnancy Registry

15/07/2016
06/02/2026
EU PAS number:
EUPAS10541
Study
Ongoing
Study identification

EU PAS number

EUPAS10541

Study ID

27036

Official title and acronym

The Mycophenolate Pregnancy Registry

DARWIN EU® study

No

Study countries

United States

Study description

The Mycophenolate Pregnancy Registry is designed as a prospective, observational registry collecting data regarding mycophenolate exposure during pregnancy, and pregnancy, fetal and infant outcomes after exposure. Early and later term pregnancy outcomes will be solicited at selected gestational time points and at the estimated date of delivery. Structural and functional birth defects identified in the perinatal period through one year of life will be collected and classified.

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Annette Stemhagen

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Genentech, Inc., Novartis Pharmaceuticals Corporation, Accord Healthcare, Inc., Alkem Lab. Ltd. Alkem Lab.Ltd. U.S. REMS Agent, Amneal Pharmaceuticals, Amta Labs Limited, Apotex Corp., Avet Lifesciences Limited, Azurity Pharmaceuticals, Inc., Biocon Pharma Limited, Concord Biotech Limited, Endo Pharmaceuticals, Inc., Hetero Labs Limited, Hikma Pharmaceuticals USA Inc., Hisun Pharmaceuticals, Jubilant Cadista Pharmaceuticals Inc., Lannett Company, Inc., Meitheal Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Rising Pharma Holdings, Inc., RK Pharma Inc., Sandoz Incorporated, Strides Pharma, Inc., Teva Pharmaceuticals USA, Inc., TWi Pharmaceuticals, Inc., VistaPharm, Inc., Wuxi Fortune Pharmaceutical Co., Ltd, Zydus Pharmaceuticals
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)